Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Risk Management Guidance Suggests Advisory Cmte Review For RiskMAPs

Mar 28 2005

• By The Pink Sheet

Related Content

FDA Unveils Rx Safety Board, Website; Postmarket Surveillance Overhaul Next

Feb 21 2005

COX-2 Retrospective Study Prompts Review By FDA, Kaiser On Merck’s Vioxx

Aug 30 2004

FDA Evaluation Of Risk Management Plans And “Tools” Needed, PhRMA Says

Aug 02 2004

Post-Marketing Safety Surveillance Should Include Data Mining, FDA Says

May 10 2004

IoM Drug Safety Study May Buy Time For FDA; Report Will Play In PDUFA IV

Nov 15 2004

Crestor, Serevent Safety Issues Push Vioxx Out Of Spotlight In Senate Hearing

Nov 22 2004

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window